Treatment satisfaction and clinical improvement after switch to fingolimod

被引：0
|
作者：
Fox, E.
Edwards, K.
Burch, J. G.
Kim, E.
Pestreich, L.
McCague, K.
Barbato, L.
机构：
[1] MS Clin Cent Texas, Round Rock, TX USA
[2] MS Ctr NE New York, Latham, NY USA
[3] Blue Ridge Res Ctr, Roanoke, VA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF NEUROLOGY | 2013年 / 260卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P543
引用
收藏
页码：S126 / S126
页数：1
相关论文
共 50 条
  • [1] PREFERMS study: fingolimod switch effect on patient retention, key clinical outcomes and patient satisfaction
    Hunter, S. F.
    Cascione, M.
    Thomas, F. P.
    Cree, B. A. C.
    Meng, X.
    Schofield, L.
    Tenenbaum, N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 782 - 782
  • [2] Multiple sclerosis disease rebound after treatment switch from fingolimod to alemtuzumab
    Willis, M.
    Pearson, O.
    Illes, Z.
    Nielsen, C.
    Sejbaek, T.
    Duddy, M.
    Petheram, K.
    van Munster, C.
    Killestein, J.
    Uitdehaag, B.
    Malmestrom, C.
    Tallantyre, E.
    Robertson, N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 664 - 665
  • [3] Switching to fingolimod in PREFERMS: Effect of treatment history and naivety on clinical, MRI and treatment satisfaction outcomes
    Hunter, Samuel F.
    Thomas, Florian P.
    Cascione, Mark
    Williams, Ian M.
    Meng, Xiangyi
    Schofield, Lesley
    Weiss, Jamie L.
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 45
  • [4] Improvement in prosocial functioning after a switch to ziprasidone treatment
    Loebel, A
    Siu, C
    Romano, S
    [J]. CNS SPECTRUMS, 2004, 9 (05) : 357 - 363
  • [5] Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
    Zhu, Chao
    Zhou, Zhen
    Roos, Izanne
    Merlo, Daniel
    Kalincik, Tomas
    Ozakbas, Serkan
    Skibina, Olga
    Kuhle, Jens
    Hodgkinson, Suzanne
    Boz, Cavit
    Alroughani, Raed
    Lechner-Scott, Jeannette
    Barnett, Michael
    Izquierdo, Guillermo
    Prat, Alexandre
    Horakova, Dana
    Havrdova, Eva Kubala
    Macdonell, Richard
    Patti, Francesco
    Khoury, Samia Joseph
    Slee, Mark
    Karabudak, Rana
    Onofrj, Marco
    Van Pesch, Vincent
    Prevost, Julie
    Monif, Mastura
    Jokubaitis, Vilija
    van der Walt, Anneke
    Butzkueven, Helmut
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (12): : 1330 - 1337
  • [6] No effect on incidence of infection after therapy switch to fingolimod
    LaGanke, C.
    Wynn, D. R.
    McCague, K.
    Barbato, L. M.
    Hashmonay, R.
    [J]. JOURNAL OF NEUROLOGY, 2013, 260 : S127 - S127
  • [7] Fingolimod treatment in clinical practice
    Harai, G.
    Dolev, M.
    Magalashvili, D.
    Stern, Y.
    Hilkevich, O.
    Hillel, M.
    Kassierer, T.
    Achiron, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 270 - 271
  • [8] Does the reason for the switch to fingolimod affect the treatment response?
    Ozakbas, S.
    Aslan, T.
    Ozdogar, A. T.
    Abasiyanik, Z.
    Sagici, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 585 - 585
  • [9] Treatment satisfaction and quality of life in patients treated with fingolimod
    Mekies, Claude
    Heinzlef, Olivier
    Jenny, Beatrice
    Ramelli, Anne-Laure
    Clavelou, Pierre
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 899 - 907
  • [10] Drug satisfaction in multiple sclerosis using fingolimod treatment
    Terzi, M.
    Evin, O.
    Terzi, Y.
    Sen, S.
    Ecem, A.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1058 - 1059
12345